  |
|
30.04.2010 Aragen
Bioscience, Inc. and CEVEC Sign License Agreement
for Human CAP®
and CAP-TTM
Technology |
|
CEVEC Pharmaceuticals
(“CEVEC”), the developer of a novel human expression
system derived from amniocytes, and Aragen Bioscience,
Inc. (“Aragen Bioscience”), a California based contract
research and development organization, announced today
the signing of a strategic license agreement. This
license enables Aragen Bioscience to offer its clients
custom recombinant human cell lines expressing
biotherapeutic proteins and antibodies as well as the
transient and stable production of preclinical and
clinical grade material.
 |
 |
|
|
|
|
|
|
|
29.04.2010
GATC Subsidiary Lifecodexx AG Develops Tests for
Prenatal Diagnostics
|
|
LifeCodexx AG (www.lifecodexx.com
) has started operational research and development work
on clinically validated diagnostic tests by using Next
Generation Sequencing technologies. The work currently
focuses on the field of prenatal diagnostics. LifeCodexx
will utilize
GATC Biotech’s
20 years of experience as well as its sequencing
laboratory, which is the European leader with a total
capacity of more than 2 terabases per year.
|
 |
|
|
|
 |
|
|
29.04.2010
Oncos Therapeutics Raises € 4 Million From Healthcap to Develop
Oncolytic Viruses Into Cancer Treatments
|
|
Oncos Therapeutics, a biotech company
developing new cancer therapeutics based on its next
generation oncolytic viruses, completed a € 4 million ($
5.5 million) investment from HealthCap. With committed
capital exceeding € 800 million, HealthCap is one of the
largest specialized providers of venture capital within
life sciences in Europe.
|
 |
|
|
|
 |
|
|
27.04.2010
Mucosis Appoints Dr. Roberto Grimaldi As Chief
Medical Officer |
|
Dutch vaccine development company
MUCOSIS B.V.
announced
today that Dr. Roberto Grimaldi, MD was appointed Chief
Medical Officer at Mucosis. Dr. Grimaldi is an
accomplished executive and consultant to the vaccine
industry who brings over 25 years of experience. As an
expert on vaccine development he will lead the Mucosis
development programs into clinical trials in the near
future.
|
 |
|
|
|
 |
|
|
27.04.2010
Oxford BioMedica Plc Annual General Meeting
|
|
Oxford Biomedica
(LSE: OXB),
a leading gene therapy company, announced today
that all resolutions proposed were duly passed at its
Annual General Meeting (AGM), held today in London.
|
 |
|
|
|
|
|
|
|
27.04.2010 MorphoSys AG Reports
Results for the First Quarter of 2010 |
|
MorphoSys AG
(FSE: MOR; Prime Standard Segment, TecDAX) today
announced its financial results for the three months
ending March 31, 2010 according to
International Financial Reporting Standards (IFRS).
Group revenues increased by 8 % to EUR 20.6 million
(Q1 2009: EUR 19.1 million) and operating profit was
EUR 4.7 million (Q1 2009: EUR 4.2 million). Net profit
amounted to EUR 3.2 million (Q1 2009: EUR 3.5 million).
As planned, MorphoSys further increased its investment
in proprietary research and development, to EUR 4.6
million (Q1 2009: EUR 4.1 million). MorphoSys's cash
position on March 31, 2010 was EUR 147.3 million
(December 31, 2009: EUR 135.1 million). The Company
re-confirmed its full year guidance 2010.
|
 |
|
|
|
 |
|
|
26.04.2010 RoACTEMRA Recommended for
Approval in Europe for the Reduction of Joint Damage and Improvement
in Physical Function in Rheumatoid Arthritis |
|
Roche
(SIX: RO, ROG; OTCQX: RHHBY) announced that
RoACTEMRA has received a recommendation for approval from the
European Medicines Agency (EMA) Committee for Medicinal Products for
Human Use (CHMP) to extend its indication to reduce the rate of
progression of joint damage and improve physical function in
patients with rheumatoid arthritis (RA), when given in combination
with methotrexate. Joint damage in RA often begins early in the
disease and can lead to permanent disability, so inhibiting this
structural damage to patients’ joints is a critical measure of the
effectiveness of an RA treatment.
|
 |
|
|
|
|
|
|
|
26.04.2010 Pevion Announces Excellent
Preclinical Results for PEV4 RSV Vaccine Candidate
|
|
Pevion Biotech
Ltd.
,
the Swiss vaccine
company, today announced that it has successfully completed the
preclinical safety and efficacy studies of its RSV vaccine candidate
PEV4. The vaccine candidate is a modern subunit vaccine candidate
against respiratory syncytial virus (RSV), which is based on a
recombinant RSV-F protein formulated with Pevion Biotech’s
proprietary and market-validated virosome technology platform. RSV
continues to be a major problem, affecting both the young and the
elderly in particular. RSV is responsible for over 900,000
hospitalizations annually in the US and Europe. The results of these
studies will be presented at the Vaccine Innovation Meeting in
Frankfurt, Germany on April 29, 2010.
|
 |
|
|
|
 |
|
|
22.04.2010 Thermo Fisher Scientific
Collaborates on Clinical Biomarker Research |
|
Thermo Fisher Scientific Inc,
the world leader in serving science, and Professor Bruno Domon,
director of the new Luxembourg Clinical Proteomics unit (LCP), today
announced a collaboration to develop workflows that overcome current
bottlenecks in biomarker discovery and assay development for
clinical proteomics research. The LCP is funded by the Fonds
National de la Recherch and is hosted at Public Research Centre for
Health (CRP-Santé).
|
 |
|
|
|
|
|
|
|
21.04.2010 Oxford BioMedica Plc Board Change
|
|
Oxford Biomedica
(LSE: OXB),
a leading gene therapy company, announced
today that Nick Woolf has informed the Board that he
wishes to step down as Chief Business Officer and
Executive Director. Nick has decided to leave the
Company purely for personal reasons as his family is
planning to move to Australia. It is anticipated that
Nick will step down on 30 June 2010, although he is
committed to a smooth transfer of his responsibilities
and has offered to extend his departure if required.
|
|
|
|
|
|
|
|
|
20.04.2010
MorphoSys to Host Q1 2010 Conference Call on April 27, 2010 |
|
MorphoSys AG
(FSE: MOR; Prime Standard Segment, TecDAX)
will publish its first three months' 2010 results on
April 27,
2010 at 7:00 a.m. CET. At 2:00 p.m. CET (1:00 p.m. BST, 8:00 a.m.
EDT), the Management Board of MorphoSys AG will host a public
conference call to present MorphoSys's financial results for the
first three months of 2010 and provide further details on the
Company's latest developments.
|
|
|
|
|
|
|
|
|
19.04.2010
New CFO Arnd Christ to
take up position at MediGene in April |
|
The biotech company
MediGene AG
(Frankfurt: MDG,
Prime Standard, TecDAX)
today announces that
the Company's new Chief Financial Officer Arnd Christ, whose
appointment was announced in March, will succeed Dr. Thomas Klaue on
April 19, 2010, and Dr. Klaue has therefore resigned with immediate
effect. The appointment of Mr Christ was scheduled for May 11, 2010,
and the change has become possible earlier because he has been able
to terminate his previous employment as Chief Financial Officer at
NovImmune AG in mid-April.
|
 |
|
|
|
|
|
|
|
19.04.2010 AACR presentations highlight
potential of Antisoma drugs AS1413 and AS1411 |
|
Antisoma plc
(LSE:
ASM; USOTC: ATSMY)
announces that its scientists and collaborators are
presenting six posters on AS1413 (amonafide L-malate)
and AS1411 this week at the annual meeting of the
American Association for Cancer Research in Washington,
DC. The presentations highlight the distinctive features
and potential of these two novel cancer drugs, both of
which are in advanced clinical testing.
|
 |
|
|
|
 |
|
|
16.04.2010 Update on legal
proceedings |
|
H.Lundbeck
A/S
(Lundbeck)
has been informed of
a favorable ruling from the City Court in Elsinore in a preliminary
injunction case in Denmark. The decision means that generic versions
of escitalopram in Denmark have to be removed from the market. The
decision can be appealed by the other side.
|
 |
|
|
|
 |
|
|
15.04.2010 New Data Suggest Oral Laquinimod May Confer
Neuroprotection in Addition to Immunomodulation in the Treatment of
Multiple Sclerosis |
|
Teva Pharmaceutical Industries Ltd.
(NASDAQ: TEVA) and
Active Biotech
(NASDAQ OMX NORDIC: ACTI) today announced
results from several studies demonstrating that laquinimod, a novel,
investigational once-daily oral immunomodulator for relapsing
remitting multiple sclerosis (RRMS) may have neuroprotective
properties in addition to its anti-inflammatory effects. These
studies were presented at the 62nd Annual Meeting of the American
Academy of Neurology (AAN).
|
|
|
|
|
|
|
|
|
14.04.2010 BioGenes Says Generic HCP Assays
Provide Insufficient Sensitivity |
|
|
BioGenes GmbH
a supplier of GMP-compliant immunoassays and
antibodies, completed a study that documents the insufficient
sensitivity of an ELISA-based generic host cell protein (HCP) assay.
The results confirm the observation of several contract
manufacturers that generic HCP assays are only of limited use for
detection of HCPs during manufacturing processes. The continued use
of generic HCP assays may lead to insufficient process documentation
and finally to safety hazards for patients. |
 |
|
|
|
|
|
|
|
|
|
|
12.04.2010 Axis-Shield and Abbott
Partner to Develop Diabetes Immunoassay |
|
Axis-Shield
(LSE:ASD, OSE:ASD),
Abbott
(NYSE: ABT) announced today that they have entered into an agreement
to develop and commercialize a haemoglobin (HbA1c) immunoassay to
run on Abbott’s flagship ARCHITECT® high throughput analyser system.
The test, which will be designed to be used to monitor treatment
efficacy in patients with diabetes, will incorporate novel
Axis-Shield technology from pioneering research at its Dundee plant.
|
 |
|
|
|
|
|
|
|
07.04.2010 Desmoteplase enters
clinical phase II in Japan in ischaemic stroke representing
Lundbecks first clinical programme in Japan |
|
H.Lundbeck
A/S
(Lundbeck)
strengthens its pipeline of pharmaceuticals
in clinical development by initiating phase I clinical studies with
Lu AE04621 in order to investigate safety, tolerability and the
pharmacokinetic profile of the drug in humans. The
placebo-controlled study is expected to enrol around 100 healthy
individuals.
|
|
|
|
|
|
|
|
|
06.04.2010 MOLOGEN AG receives
funding to develop a DNA vaccine against hepatitis B |
|
The DNA specialists from Berlin are
intensifying their work on developing innovative and improved
DNA-based vaccines. This is a response to a high demand - with an
interesting market potential.
The
Berlin biotech company
MOLOGEN AG
has received funding for the pre-clinical
development of a MIDGE®-based vaccine against hepatitis B. The
project has already commenced and is being carried out jointly with
Synvolux Therapeutics B. V., a company based in the Netherlands.
|
 |
|
|
|
|
|
|
|
01.04.2010 MediGene
Signs Agreement with Meditrina for the Commercialization of Veregen®
in Greece and Cyprus
|
|
Today the biotech company
MediGene AG
(Frankfurt: MDG,
Prime Standard, TecDAX) has signed a
license and supply agreement with Meditrina Pharmaceuticals for the
supply and commercialization of Veregen® in Greece and
Cyprus. Meditrina will promote and distribute Veregen®
for the treatment of genital warts in both territories. Upon the
achievement of specific milestones, MediGene will be entitled to
successive payments totaling up to 900 thousand euros, and will
receive the first milestone payment upon the initiation of the
approval procedure in Greece. In addition, MediGene will supply
Meditrina with finished product and will receive double-digit
royalties on net sales.
|
|
All rights reserved